Author

K. Luddy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Approach:statistical model· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

M. Robertson-Tessi· 3 shared A. El-Kenawi· 2 shared A. Ibrahim-Hashim· 2 shared C. Harmon· 2 shared J. West· 2 shared R. Bravo· 2 shared r. gillies· 2 shared A. Anderson· 1 shared

Activity by Year

2018-2019 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Robertson-Tessi

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Lymph Nodes Inhibit T-cell Effector Functions Locally by Establishing Acidic Niches

H. Wu, V. Estrella, P. Enriquez-Navas, A. El-Kenawi, S. Russell, D. Abrahams, A. Ibrahim-Hashim, D. Longo, Y. Reshetnyak, K. Luddy, M. Damaghi, S. R. Pillai, M. Beatty, S. Pilon-Thomas, P. Swietach, r. gillies

The paper shows that acidic niches in lymph nodes inhibit T-cell effector functions by blocking lactic acid efflux and reducing glycolysis, keeping T-cells in a state of stasis.

bioRxiv · Jul 2, 2019 · PreprintPhysiology

Intermittent hormonal therapy shows similar outcome than SOC in ER+ breast cancer preclinical model.

P. M. Enriquez Navas, L. Garcia, M. Abdalah, O. Stringfield, K. Luddy, S. Hassan, R. J. Gillies, R. A. Gatenby

This study shows intermittent hormonal therapy achieves similar tumor control as standard-of-care in ER+ breast cancer models with reduced drug use and preserved sensitive cell phenotypes.

bioRxiv · Jan 8, 2019 · PreprintCancer Biology

Acidity promotes tumor progression by altering macrophage phenotype in prostate cancer

A. El-Kenawi, C. Gatenbee, M. Robertson-Tessi, R. Bravo, J. Dhillon, Y. Balagurunathan, A. Berglund, N. Visvakarma, A. Ibrahim-Hashim, J. Choi, K. Luddy, R. Gatenby, S. P. Thomas, A. Anderson, B. Ruffell, R. Gillies

This study shows that tumor acidity promotes prostate cancer by altering macrophage phenotype, both in vitro and in vivo, and is supported by in silico modeling.

bioRxiv · Nov 26, 2018Immunology

Evolutionary exploitation of PD-L1 expression in hormone receptor positive breast cancer

J. West, D. Park, C. Harmon, D. Williamson, P. Ashcroft, D. Maestrini, A. Ardaseva, R. Bravo, P. Sahoo, H. Khong, K. Luddy, M. Robertson-Tessi

The paper models how timing of aromatase inhibitor and immune checkpoint inhibitor therapies affects tumor burden and metastatic potential in hormone receptor positive breast cancer.

bioRxiv · Oct 26, 2018 · PreprintCancer Biology

The immune checkpoint kick start: Optimization of neoadjuvant combination therapy using game theory

J. West, M. Robertson-Tessi, K. Luddy, D. S. Park, D. F. K. Williamson, C. Harmon, H. T. Khong, J. Brown, A. R. A. Anderson

The paper develops a mathematical model to optimize neoadjuvant combination therapy for ER+ breast cancer by balancing tumor burden and metastatic potential using game theory.

bioRxiv · Jun 18, 2018Cancer Biology